Assessment of endoscopic activity lndex and biological lnflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level

被引:85
作者
Denis, Marie-Arrhelle
Reenaers, Catherine
Fontaine, Fernand
Belaiche, Jacques
Louis, Edouard
机构
[1] Clin St Joseph, Dept Gastroenterol, Liege, Belgium
[2] Univ Liege, GIGA Res, B-4000 Liege, Belgium
[3] CHU, Dept Gastroenterol, Liege, Belgium
关键词
Crohn's disease; CRP; CDEIS; cytokines;
D O I
10.1002/ibd.20178
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI) > 150, may have normal Greactive protein (CRP) serum levels. In such cases, it is difficult to know whether these patients have really active disease or rather functional symptoms. This distinction is important to decide the most appropriate treatment. The aim of our work was to assess intestinal and colonic lesions in such patients and to look for biological markers potentially associated with endoscopic activity of the disease. Methods: We included 28 consecutive CD patients with CDAI >150 and a normal CRP level. These patients underwent a full colonoscopy with Crohn's Disease Endoscopy Index of Severity (CDEIS) calculation, fecal calprotectin, blood fibrinogen, acid a-I glycoprotein, and erythrocyte sedimentation rate measurement. The Harvey-Bradshaw score was also calculated. Serum ILI beta, IL6, IL8, sIL2R, and sTNFR2 were measured. Results: The median CDAI was 181 (151-485). Almost all (92.9%) these patients had endoscopic lesions, but the majority had only mild lesions (CDEIS : 6). No correlation was found between CDEIS and any of the clinical or biological markers. However, all the patients with significant endoscopic lesions (defined by a CDEIS >6) had previous surgical intestinal resection and lesions involving the anastomosis. Conclusions: Patients with elevated CDAT and normal CRP have only mild mucosal lesions of CD. Most significant lesions may be observed at the anastomosis and proximal to it in previously operated patients. None of the biological markers tested was associated with these endoscopic lesions.
引用
收藏
页码:1100 / 1105
页数:6
相关论文
共 31 条
[1]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[2]   The genetics of inflammatory bowel disease [J].
Bonen, DK ;
Cho, JH .
GASTROENTEROLOGY, 2003, 124 (02) :521-536
[3]   Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels [J].
Carlson, CS ;
Aldred, SF ;
Lee, PK ;
Tracy, RP ;
Schwartz, SM ;
Rieder, M ;
Liu, KA ;
Williams, OD ;
Iribarren, C ;
Lewis, EC ;
Fornage, M ;
Boerwinkle, E ;
Gross, M ;
Jaquish, C ;
Nickerson, DA ;
Myers, RM ;
Siscovick, DS ;
Reiner, AP .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (01) :64-77
[4]   CORRELATIONS BETWEEN CLINICAL ACTIVITY, ENDOSCOPIC SEVERITY, AND BIOLOGICAL PARAMETERS IN COLONIC OR ILEOCOLONIC CROHNS-DISEASE - A PROSPECTIVE MULTICENTER STUDY OF 121 CASES [J].
CELLIER, C ;
SAHMOUD, T ;
FROGUEL, E ;
ADENIS, A ;
BELAICHE, J ;
BRETAGNE, JF ;
FLORENT, C ;
BOUVRY, M ;
MARY, JY ;
MODIGLIANI, R ;
COLOMBEL, JF ;
CORTOT, A ;
LESCUT, D ;
BITOUN, A ;
LEMANN, M ;
SALMERON, M ;
THEROND, JP ;
VERNISSE, B ;
SEE, A ;
RAOUL, JL .
GUT, 1994, 35 (02) :231-235
[5]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[6]   SERUM LEVELS OF C-REACTIVE PROTEIN IN CROHNS-DISEASE AND ULCERATIVE-COLITIS [J].
FAGAN, EA ;
DYCK, RF ;
MATON, PN ;
HODGSON, HJF ;
CHADWICK, VS ;
PETRIE, A ;
PEPYS, MB .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1982, 12 (04) :351-359
[7]   Clinically active Crohn's disease in the presence of a low C-reactive protein [J].
Florin, THJ ;
Paterson, EWJ ;
Fowler, EV ;
Radford-Smith, GL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (03) :306-311
[8]   Faecal calprotectin in the assessment of Crohn's disease activity [J].
Gaya, DR ;
Lyon, TDB ;
Duncan, A ;
Neilly, JB ;
Han, S ;
Howell, J ;
Liddell, C ;
Stanley, AJ ;
Morris, AJ ;
Mackenzie, JF .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2005, 98 (06) :435-441
[9]   Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities [J].
Hanauer, SB .
INFLAMMATORY BOWEL DISEASES, 2006, 12 :S3-S9
[10]  
HARVEY RF, 1980, LANCET, V1, P514